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level of educational effectiveness was on par with or greater than
previously received in-person DES training. This effectiveness
translated into greater content retention and higher motivation
to learn. A study review revealed that return on investment for
corporate online training approaches 30% in the ﬁrst 2 years of
deployment and more than 100 percent after 4-years. For both
DES professionals engaged in training, and students, travel and
accommodation costs were reduced to zero, while costs due to
lost workdays were reduced by 50% for students and 100% for
DES professionals. CONCLUSION: The capability to lower
training budgets for DES education removes a signiﬁcant barrier
to the diffusion of this modeling technique. The savings in both
cost and resources allows knowledgeable DES professionals to
invest in the creation of online courses without the expense and
difﬁculty of scheduling teaching sessions.
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OBJECTIVES: Importance of animal health economics has been
widely acknowledged. The objective of this project was to evalu-
ate the perspective and type of analyses used in animal health
economic studies. METHODS: An electronic search in EMBASE
and MEDLINE was conducted from 1987 onwards, using
the key words economic, cost-effectiveness, cost-beneﬁt, cost-
minimization, cost-cost analysis, combined with the respective
kind of animal (cow, pig, horse, dog, cat). Among 631 articles, 68
abstracts were included for this review (34 studies in cows, 13 in
pigs, 3 in horses, 14 in dogs, 4 in cats), the others did not
represent health economic studies. RESULTS: Study perspective
was stated in only one abstract but could be assumed from the
content in the other studies, being that of the animal owner in all
but one. Cost-effectiveness was the type of study most often used
(37/68), followed by cost-beneﬁt studies (22/68). Again, the kind
of study often had to be assumed as it was only mentioned in
22% of the abstracts (15/68). The main ﬁeld of investigation was
that of immunization. CONCLUSION: The fact that fundamen-
tal information on the perspective or type of study was rarely
stated in the abstracts might be due to the fact that guidelines on
animal health economics are missing. The predominant perspec-
tive, namely that of the animal owner differed from those found
in human health economics. It reﬂects the fact that insurance or
public coverage of costs is not widespread in animal health;
accordingly the owner is the main payer. If compared with
human health economics the share of cost-beneﬁt analyses was
higher, as there is a market price especially for farm animals and
their products. Further efforts in this ﬁeld might improve quality
of study presentation and probably raise interest for health eco-
nomic studies on veterinary pharmaceuticals.
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OBJECTIVES: The U.S. Centers for Medicare and Medicaid
Services (CMS) has adopted a Medicare quality incentive pay-
for-performance concept. This study explores CMS’s implemen-
tation of the Physician Quality Reporting Initiative (PQRI),
including measurement development, reporting guidelines and
the proposed methods by which physicians will be compensated
for participation. METHODS: PQRI guidance provided by CMS
was collected, arranged in order of issuance, abstracted and
analyzed. Ongoing corrections and modiﬁcations were noted as
appropriate. A compilation of suggested PQRI-relevant resources
was also created as part of the project. RESULTS: The Tax Relief
and Healthcare Act (TRHCA) Division B, Title I, Section 101
provides statutory authority for PQRI. The TRHCA deﬁnes
eligible professionals; quality measures themselves, as well as
reporting methods and processes for obtaining bonus payment.
The initial reporting period commences July 1, 2007 and ends
December 31, 2007. During this period 74 quality measures may
be reported. If 4 or more measures are applicable to the physician
practice, the practitioner must report at least 3 correctly for 80%
of applicable cases. If 3 or fewer measures are applicable to the
practice, the practitioner must report each of them correctly for
80% of the cases. Cases may be either visits or patients, depend-
ing upon the particular measure. Professionals that report
successfully are eligible for a 1.5% bonus payment (pay-for-
performance), subject to a cap. The bonus payment calculation
method is determined by using total allowed charges for covered
professional services that are furnished during the reporting
period and are paid under the CMS Physician Fee Schedule.
CONCLUSION: Physician practices must adhere to the appro-
priate method for coding and reporting quality measures in order
to obtain relevant bonus compensation. It is vital for physician
practice decision-makers to understand and comply with the
CMS reporting methodology in order to reap the accompanying
monetary compensation.
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OBJECTIVES: Greater emphasis for economic evaluations in
health care reimbursement decision-making has brought about
the need for models that are accurate and methodologically
sound. Although guidelines exist suggesting appropriate methods
for model validation, there remains a paucity of practical
guidance outlining steps to ensure that outcomes have been
appropriately validated. The objective was to establish a process
outlining a series of practical tests to ensure consistent model
validation. METHODS: A systematic search of the literature was
conducted to identify modeling guidelines and published model-
ing studies discussing validation techniques. Results from the
literature search were used to develop practical steps to ensure
consistent model validation. RESULTS: A list of validation tests
were compiled and collated following a review of 15 guideline
publications on model validation. Model validation should not
only encompass checking for calculation errors or structural
inconsistencies, but also include a complete synthesis of the
evidence-based data used to produce results. Initially, the model
structure should be reviewed for face validity, assessing the eco-
nomic and clinical assumptions that include consulting scientiﬁc
experts, external to the model development process. Secondly,
convergent validity should be conducted where a series of tests
are performed comparing if results from other independently
developed models draw similar conclusions. Internal validity
involves a series of procedures to ensure the basic model frame-
work and mathematical calculations are consistent. Test-runs
should be performed including a replication test, and extensive
sensitivity analyses, whereby a series of extreme/hypothetical
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assumptions are explored. Further assurances of internal validity
include the replication of the model in another software. CON-
CLUSION: Approaches to model validation should be included
as part of any publication. Budgetary and time allocation should
take model validation into account given the increased impor-
tance placed on the outcomes of health economic models.
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OBJECTIVES: The use of computational models to assess thera-
peutic alternatives has been growing in importance in the eco-
nomic evaluation of health technologies and services during the
last years, becoming a more relevant and helpful tool for decision
making in health care. Until now, two types of models have been
used: decision trees and Markov chains, nevertheless, they both
show important limitations when addressing complex processes
or pathologies, and that’s why interest in, and use of discrete
event simulation(DES) is growing, specially in economic evalua-
tion and medical decision making related journals. The objective
of this study was to perform a bibliographic review of DES
studies, and to evaluate their advantages ad limitations where
compared with other broadly used decision analytic model tech-
niques. METHODS: A structured bibliographic search using
Medline, principally, was performed to search in the scientiﬁc
literature the keywords: Health technology, computer simula-
tion, economic evaluation models and discrete event simulation.
A system of selection of the search based on authors peer reviews
and expert criteria was established. RESULTS: Forty-two papers
were selected using DES alone or combined with Markov chains
and decision trees. The result reﬂects the increasing number of
the DES in after 1998, specially in the last 5 years. A classiﬁca-
tion of the selected articles was performed. These classiﬁcation
revealed the use of secondary data in these model development.
Studies come in a highest percentage from UK, USA, and
Holland, the temporal perspective was from less than 1 up to 50
years; sensitivity analysis was performed in the mentioned studies
and Simul8, Arena, MS Excel were the most frequent used soft-
wares. CONCLUSION: The results reﬂect that the use and
acceptance of DES is growing internationally in health technol-
ogy and health care analysis, so it would be an useful tool to
simulate some complicated system and processes.
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OBJECTIVES: To analyze a health resources utilization claim
database in order to derive direct health costs of treating patients
with Fibromyalgia under routine medical practice at PCS.
METHODS: A 12-month retrospective study was performed
using computerized medical records from a health provider data-
base; BSA. Analysis was conducted from a 3r-payer perspective
during the year 2006. Health resources utilization included both
those of the primary care (PC) level (drugs, complementary tests,
medical visits, etc.) and those of the specialized care (SC) as well.
SC included emergency visits, hospitalizations, and tests and
drugs prescribed by specialist. Men and women above 18-years
included in the data base (n = 63,526) were analyzed. Fibromy-
algia was diagnosed according with CIE-10 criteria. Descriptive
statistics and ANCOVA models were used. RESULTS: One-
thousand-eighty-one subjects [96.7% women, 54.2 (10.1) years]
fulﬁlled CIE-10 criteria for Fibromyalgia amongst the 63,526
database subjects: 1.7%. Charlson index was no different in
Fibromyalgia patients vs controls (the rest of sample analyzed),
p = 0.212. After adjusting by age and sex, yearly total health
costs per patient were €614 higher (+66%) on average in Fibro-
myalgia than in controls; €1,550 (95% CI: 1,341–1,760) vs.
€937 (927–945), p < 0.0001. Both PC and SC annual costs were
signiﬁcantly higher in Fibro patients; mean per patient adjusted
difference of €395 (276–513, p < 0.0001) and €219 (74–364,
p = 0.003), respectively. Total annual drug costs were consider-
ably higher in patients with Fibromyalgia; €591 (485–696) vs.
€361 (356–366), p < 0.0001. Age correlated moderate but sig-
niﬁcantly with yearly PC, drug and total per patient health costs;
r = 0.324, 0.325, and 0.278, respectively, p < 0.001 in all cases.
CONCLUSION: Compared with controls, subjects with Fibro-
myalgia were associated to higher annual total direct health costs
in the primary care setting. Drugs represented a considerable
portion of health resources costs devoted to these patients. Age,
but not sex, was associated with higher costs.
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OBJECTIVES: To analyze the impact of PRO measurements on
longitudinal direct health costs when treating Fibromyalgia
under routine medical practice at PCS. METHODS: Retrospec-
tive sub-analysis of subjects above 18-years, with Fibromyalgia
according to CIE-10, included in a claim database (BSA), who
received the point-administration of FIQ, EQ-5D and BPI ques-
tionnaires after 12-months of health resources utilization record
and deriving total health direct costs. Resources included emer-
gency visits, hospitalizations, complementary tests, drugs and
medical visits occurred both at primary (PC) and specialized care
(SC) level. RESULTS: One-thousand-eighty-one subjects [96.7%
women, 54.2 (10.1) years] fulﬁlled CIE-10 criteria for Fibromy-
algia amongst 63,526 subjects in the database. PRO question-
naires were administered to a random sample of 200 patients
[97.5% women, 53.0 (8.5) years] showing no statistically differ-
ences in health resources utilization and costs vs. the other Fibro-
myalgia patients. Patient disease impact was severe [total FIQ;
71.7 (16.9)] showing weak but signiﬁcant correlation with total
annual health costs; r = 0.202 (p = 0.004). Work/domestic-
interference BPI-item correlated signiﬁcantly, but also weak, with
PC, drugs and total health costs; r = 0.216, 0.218, 0.242, respec-
tively (p < 0.01 in all cases). BPI sleep interference correlated
slightly but signiﬁcant with total costs; r = 0.203 (p = 0.004).
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